Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.

Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL

Clinical nutrition ESPEN20 Mar 2021Cited by 23 (Europe PMC)

PMID34024550DOI10.1016/j.clnesp.2021.03.011PepBankPUB-34024550

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF receiving teduglutide, median time to response was 4.3 months.
In plain wordsIn adults with SBS-IF receiving teduglutide, median response time was 4.3 months.
Peptide
Teduglutide
Outcome
Not applicableMedian time to response
Study
n = 34
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Median time to response
4.3 months
overall, 34 teduglutide-treated patients
Source sentences
Summary
A total of 34 patients were included in this analysis; overall median time to response was 4.3 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455001
02HumanObservational studyEfficacy outcome
In adults receiving teduglutide, stoma presence predicted response (HR 5.6, 95% CI 1.4-21.9, p = 0.013).
In plain wordsIn adults receiving teduglutide, a stoma was linked to a higher response rate than no stoma.
Peptide
Teduglutide
Outcome
IncreaseStoma association with response
Study
n = 34
Comparator
No stoma
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Hazard ratio
5.6 HR
stoma vs no stoma
95% CI of hazard ratio
1.4 to 21.9 HR
stoma vs no stoma
Source sentences
Summary
The presence of stoma predicted a positive response to teduglutide (hazard ratio [HR]: 5.6; 95% confidence interval [CI]: 1.4-21.9; p = 0.013).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455002
03HumanObservational studyEfficacy outcome
In adults receiving teduglutide, vascular disease versus IBD was negatively associated with response (HR 0.2, CI 0.0-0.8, p = 0.015).
In plain wordsIn adults receiving teduglutide, vascular disease was linked to less response than inflammatory bowel disease.
Peptide
Teduglutide
Outcome
DecreaseVascular etiology association with response
Study
n = 34
Comparator
Inflammatory bowel disease
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Hazard ratio
0.2 HR
vascular disease vs IBD as cause of resection
95% CI of hazard ratio
0 to 0.8 HR
vascular disease vs IBD as cause of resection
Source sentences
Summary
Vascular disease (vs. inflammatory bowel disease [IBD]) as cause of major intestinal resection (HR: 0.2; 95% CI: 0.0-0.8; p = 0.015)
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455003
04HumanObservational studyEfficacy outcome
In adults receiving teduglutide, ileocecal valve presence was negatively associated with response (HR 0.1, CI 0.0-0.8, p = 0.047).
In plain wordsIn adults receiving teduglutide, an ileocecal valve was linked to less response than no valve.
Peptide
Teduglutide
Outcome
DecreaseIleocecal valve association with response
Study
n = 34
Comparator
No ileocecal valve
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Hazard ratio
0.1 HR
ileocecal valve present vs absent
95% CI of hazard ratio
0 to 0.8 HR
ileocecal valve present vs absent
Source sentences
Summary
presence of ileocecal valve (HR: 0.1; 95% CI: 0.0-0.8; p = 0.047), and female sex (HR: 0.3; 95% CI: 0.1-1.0; p = 0.026) are negatively associated with response.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455004
05HumanObservational studyEfficacy outcome
In adults receiving teduglutide, female sex was negatively associated with response (HR 0.3, CI 0.1-1.0, p = 0.026).
In plain wordsIn adults receiving teduglutide, female sex was linked to less response than male sex.
Peptide
Teduglutide
Outcome
DecreaseSex association with response
Study
n = 34
Comparator
Male sex
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Hazard ratio
0.3 HR
female vs male sex
95% CI of hazard ratio
0.1 to 1 HR
female vs male sex
Source sentences
Summary
female sex (HR: 0.3; 95% CI: 0.1-1.0; p = 0.026) are negatively associated with response.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455005
06HumanObservational studyEfficacy outcome
In teduglutide-treated adults, mean response times were 3.6 months (SD 1.1, n = 27) early and 10.0 months (SD 6.1, n = 7) late.
In plain wordsIn adults receiving teduglutide, early responders had shorter response times than late responders.
Peptide
Teduglutide
Outcome
DecreaseResponse time in early versus late responders
Study
n = 34
Comparator
Late responders
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Mean time to response
3.6 months
early responders (n = 27)
SD of time to response
1.1 months
early responders (n = 27)
Mean time to response
10 months
late responders (n = 7)
SD of time to response
6.1 months
late responders (n = 7)
Source sentences
Summary
The mean times to response were 3.6 (standard deviation (SD): 1.1) months for early responders (n = 27) and 10.0 (SD: 6.1) months for late responders (n = 7).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455009
07HumanObservational studyEfficacy outcome
In teduglutide-treated adults, colon-in-continuity occurred in 51.9% of early versus 100% of late responders (p < 0.05).
In plain wordsIn adults receiving teduglutide, early responders had colon-in-continuity less often than late responders.
Peptide
Teduglutide
Outcome
DecreaseColon continuity in early versus late responders
Study
n = 34
Comparator
Late responders
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Colon-in-continuity
51.9%
early responders
Colon-in-continuity
100%
late responders
Source sentences
Summary
Fewer early responders had colon-in-continuity (51.9%) and ileocecal valve (0.0%) compared to late responders (100% and 28.6%, respectively; both p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455010
08HumanObservational studyEfficacy outcome
In teduglutide-treated adults, ileocecal valves occurred in 0.0% of early versus 28.6% of late responders (p < 0.05).
In plain wordsIn adults receiving teduglutide, early responders had an ileocecal valve less often than late responders.
Peptide
Teduglutide
Outcome
DecreaseIleocecal valve in early versus late responders
Study
n = 34
Comparator
Late responders
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Ileocecal valve present
0%
early responders
Ileocecal valve present
28.6%
late responders
Source sentences
Summary
Fewer early responders had colon-in-continuity (51.9%) and ileocecal valve (0.0%) compared to late responders (100% and 28.6%, respectively; both p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455011
09HumanObservational studyEfficacy outcome
In teduglutide-treated adults, mean colon remaining was 24.6% in early versus 57.1% in late responders (p = 0.016).
In plain wordsIn adults receiving teduglutide, early responders had less colon remaining than late responders.
Peptide
Teduglutide
Outcome
DecreaseColon remaining in early versus late responders
Study
n = 34
Comparator
Late responders
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Mean colon remaining
24.6%
early responders
Mean colon remaining
57.1%
late responders
Source sentences
Summary
Early responders had a lower mean percentage of colon remaining compared to late responders (24.6% vs. 57.1%, respectively; p = 0.016).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455012
10HumanObservational studyEfficacy outcome
In adults receiving teduglutide, IBD was associated with shorter response time than vascular disease (p < 0.05).
In plain wordsIn adults receiving teduglutide, IBD was linked to faster response than vascular disease.
Peptide
Teduglutide
Outcome
DecreaseTime to response by etiology
Study
n: not reported in source
Comparator
Vascular disease
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
In subgroup analyses, patients with IBD (vs. vascular disease), with (vs. without) a stoma, and without (vs. with) colon-in-continuity had a shorter time to response (all p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455006
11HumanObservational studyEfficacy outcome
In adults receiving teduglutide, a stoma was associated with shorter response time than no stoma (p < 0.05).
In plain wordsIn adults receiving teduglutide, a stoma was linked to faster response than no stoma.
Peptide
Teduglutide
Outcome
DecreaseTime to response by stoma
Study
n: not reported in source
Comparator
Without stoma
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
In subgroup analyses, patients with IBD (vs. vascular disease), with (vs. without) a stoma, and without (vs. with) colon-in-continuity had a shorter time to response (all p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455007
12HumanObservational studyEfficacy outcome
In adults receiving teduglutide, absence of colon-in-continuity was associated with shorter response time (p < 0.05).
In plain wordsIn adults receiving teduglutide, no colon-in-continuity was linked to faster response than colon-in-continuity.
Peptide
Teduglutide
Outcome
DecreaseTime to response by colon continuity
Study
n: not reported in source
Comparator
Colon-in-continuity
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
In subgroup analyses, patients with IBD (vs. vascular disease), with (vs. without) a stoma, and without (vs. with) colon-in-continuity had a shorter time to response (all p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension.
Summary · context
Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits.
Report a problemFND-3402455008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.